When researchers with a Phase III trial directly compared Kyprolis in combination with low-dose Decadron®(dexamethasone) versus Velcade and low-dose Decadron in patients with relapsed multiple myeloma, they found that patients treated with Kyprolis lived twice as long without a worsening of disease.1
Patients with multiple myeloma who have become refractory—or resistant—to the drugs Revlimid®(lenalidomide) and Velcade have limited treatment options. This makes Kyprolis an intriguing treatment option. It belongs to a class of drugs known as proteasome inhibitors, which work by preventing the breakdown of protein in cancer cells, triggering their death.
Results from a worldwide multicenter study found that patients with relapsed multiple myeloma treated with Kyprolis lived twice as long without a worsening of disease compared with Velcade. Kyprolis-treated patients survived on average almost 19 months compared with only nine months for those receiving Velcade.
(http://news.cancerconnect.com/kyprolis-carfilzomib-appears-more-effective-than-velcade-bortezomib-in-patients-with-relapsed-multiple-myeloma/#_ednref1 "1") FDA Grants Priority Review for Amgen’s Supplemental New Drug Application for Expanded Labeling of Kyprolis® (Carfilzomib) in Relapsed Multiple Myeloma [news release]. Amgen website. Available at: . Accessed October 16, 2015.
Copyright © 2018 CancerConnect. All Rights Reserved.